Trial Profile
A Phase II Study of Paclitaxel Protein Bound + Gemcitabine + Cisplatin + Paricalcitol as Pre-operative Treatment in Patients With Untreated Resectable, Borderline Resectable and Locally Advanced Adenocarcinoma of the Pancreas
Status:
Active, no longer recruiting
Phase of Trial:
Phase II
Latest Information Update: 20 Apr 2023
Price :
$35
*
At a glance
- Drugs Cisplatin (Primary) ; Gemcitabine (Primary) ; Paclitaxel (Primary) ; Paricalcitol (Primary)
- Indications Adenocarcinoma; Pancreatic cancer
- Focus Therapeutic Use
- 13 Apr 2023 Planned End Date changed from 1 Mar 2023 to 1 Jul 2024.
- 13 Apr 2023 Planned primary completion date changed from 31 Dec 2022 to 31 Dec 2023.
- 15 Feb 2022 Planned End Date changed from 1 Mar 2022 to 1 Mar 2023.